2. Search Result
Search Result
Results for "

Mps1/TTK-IN-1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101340
    Luvixasertib
    5+ Cited Publications

    CFI-402257

    		 Mps1 Cancer
    CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity [1].
    Luvixasertib
  • HY-101340A
    Luvixasertib hydrochloride
    5+ Cited Publications

    CFI-402257 hydrochloride

    		 Mps1 Cancer
    CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity [1].
    Luvixasertib hydrochloride
  • HY-116470
    Mps1/TTK-IN-1

    		Mps1 Cancer
    Mps1/TTK-IN-1 (Compound cpd-5), a derivative of NMS-P715 (HY-12382), is a Mps1 kinase inhibitor with an IC50 of 9.2 nM and a Kd of 1.6 nM. Mps1/TTK-IN-1 specifically targets the ATP-binding pocket of the Mps1 kinase. Mps1/TTK-IN-1 maintains inhibitory activity against Mps1 drug-resistant mutants (C604Y, C604W) with IC50 values of 170 and 19 nM and Kd values of 471 and 349 nM. Mps1/TTK-IN-1 can block the phosphorylation of kinetochore protein KNL1 mediated by Mps1, interfere with the spindle assembly checkpoint function, prevent the correct separation of chromosomes, and thereby inhibit the mitosis and proliferation of tumor cells [1].
    Mps1/TTK-IN-1
  • HY-116190
    CFI-401870

    		Mps1 DNA/RNA Synthesis Cancer
    CFI-401870 is an orally active threonine tyrosine kinase (TTK (Mps1)) inhibitor with an IC50 of 3.1 nM. CFI-401870 exhibits IC50s against PLK4, KDR, AURKA and other kinases such as AURKB/INCENP were all greater than 1 μM.CFI-401870 inhibits the growth of various cancer cells, causing chromosome lag, an increase in aneuploidy and cell cycle arrest. CFI-401870 can be used for the study of cancers such as colon cancer [1].
    CFI-401870
  • HY-101340AR
    Luvixasertib hydrochloride (Standard)

    CFI-402257 hydrochloride (Standard)

    		 Mps1 Reference Standards Cancer
    Luvixasertib (hydrochloride) (Standard) is the analytical standard of Luvixasertib (hydrochloride) (HY-101340A). This product is intended for research and analytical applications. CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity [1].
    Luvixasertib hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: